期刊文献+

共同抑制mTORC2和热休克蛋白90对多发性骨髓瘤细胞凋亡的影响

Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways
原文传递
导出
摘要 目的探讨共同抑制mTORC2信号通路和热休克蛋白90对多发性骨髓瘤(MM)细胞AKT蛋白表达及细胞凋亡的影响。方法采用雷帕霉素(20nmol/L)、17-烯丙胺-17-脱甲氧格尔德霉素(17-AAG)(600nmol/L)分别及两药联合处理MM细胞株U266、KM3细胞0、8、24、48h,MTT法检测其对细胞增殖的影响;流式细胞术检测其对细胞凋亡及细胞周期的影响;Westernblot法检测其对p-AKT(ser473)、P—AKT(thr450)、P.S6($235/236)及AKT蛋白表达的影响。结果与空白对照组比较,雷帕霉素、17一AAG分别及两药联合后均可抑制U266、KM3细胞增殖,尤以联用后抑制作用最为明显(P值均〈0.05);均可使细胞周期阻滞在G。期,尤其在作用48h时周期阻滞最明显(P值均〈0.01);处理48h后空白对照组、雷帕霉素组、17-AAG组、两药联用组KM3细胞的凋亡率分别为(12.21±0.89)%、(18.88±1.83)%、(21.04±0.60)%、(60.07±2.13)%,U266细胞的凋亡率分别为(8.72±0.15)%、(16.45±0.65)%、(17.14±0.59)%、(54.25:t=1.76)%,与空白对照组比较差异均有统计学意义,两药联用组促凋亡作用更为明显(P值均〈O.01)。雷帕霉素作用48h后可抑制mTORC2信号通路;单用雷帕霉素或17-AAG时可降低AKT蛋白的表达,两药联用作用更为明显(P值均〈0.01)。结论共同抑制mTORC2和HSP90活性可降低AKT蛋白的表达,在体外可明显促进MM细胞株U266、KM3细胞的凋亡。 Objective To explore apoptosis of multiple myeloma (MM) cells and its mechanism by the combined inhibition of mTORC2 signaling pathway and heat shock protein 90. Methods The effects of Rapamycin, 17-AAG and the combination on proliferation of MM cell lines U266 and KM3 were assessed using MTT at different time points (0, 8, 24, 48 hour). Cell apoptosis and cell cycle distribution were measured by flow cytometry. The specific proteins p-AKT (ser473), p-AKT (thr450), p-S6 ($235/236) and AKT were detected by Western blotting. Results Rapamycin, 17-AAG and the combination suppressed the proliferation of MM cell lines U266 and KM3, especially the combination of Rapamycin and 17-AAG synergistically inhibited the proliferation (P〈0.05); Rapamycin induced G, arrest both at 24 and 48 hours, 17-AAG also induced G~ arrest, especially at 48 hours (P〈0.01); Rapamycin, 17-AAG alone decreased the expression of AKT and induced MM cell apoptosis to some extent (P〈0.01); Chronic rapamycin treatment inhibited mTORC2; Inhibition of both mTORC2 and chaperon pathways degraded AKT and induced MM cell apoptosis, which was significantly higher than that of any single agent (P〈 0.01 ). Conclusion Inhibition of both mTORC2 and chaperon pathways decreased the expression of AKT to induce apoptosis of MM cells in vitro.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第9期780-784,共5页 Chinese Journal of Hematology
基金 国家自然科学基金(81470361) 湖南省科学技术厅科技计划(2013SK3057)
关键词 雷帕霉素 多发性骨髓瘤 细胞凋亡 mTORC2信号通路 HSP90热休克蛋白 质类抑制剂 Rapamycin Multiple myeloma Apoptosis mTORC2 HSP90 heat-shock proteins inhibitors
  • 相关文献

参考文献20

  • 1Ramakrishnan V, Kimlinger T, Haug J, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway [ J ]. PLoS One, 2012, 7 ( 11 ): e50005.
  • 2Zhang J, Choi Y, Mavromatis B, et al. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway [J]. Oncogene. 2003.22(40): 6289-6295.
  • 3Zhang F, Lazorchak AS, Liu D, et al. Inhibition of the mTORC2 and chaperone pathways to treat leukemia [J]. Blood, 2012, 119 (25): 6080-6088.
  • 4黄灵娟,马艳萍,杨薏蓉,杨林花.HSP90表达与人多发性骨髓瘤细胞迁移力的相关性研究[J].中国实验血液学杂志,2010,18(2):372-375. 被引量:3
  • 5Usmani SZ, Chiosis G. HSP90 inhibitors as therapy for multiple myeloma [ J ]. Clin Lymphoma Myeloma Leuk, 2011 (Suppl 1 ): $77-$81.
  • 6Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy I Jl. Oncogene, 2010, 29 (26):3733-3744.
  • 7Huston A, Leleu X, Jia X, et al. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxieity in the bone marrow microenvironment ~J~. Clin Cancer Res, 2008, 14 (3): 865-874.
  • 8Oh WJ, Jacinto E. mTOR complex 2 signaling and functions EJ~. Cell Cycle, 2011, 10( 14):2305-2316.
  • 9Kaizuka T, Hara T, Oshiro N, et al. Ttil and Tel2 are critical factors in mammalian target of rapamycin complex assembly [J]. J Biol Chem, 2010, 285(26): 20109-20116.
  • 10Takai H, Wang RC, Takai KK, et al. Tel2 regulates the stability of PI3K-related protein kinases ~J~. Cell, 2007, 131 (7):1248-1259.

二级参考文献10

  • 1Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF) -driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 ( SAPK2 /p38 ) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem, 2000; 275 (14) : 10661 - 10672.
  • 2Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor- met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res, 2000;60 (2): 342-349.
  • 3Ferrarini M, Heltai S, Zocchi R, et al. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer, 1992; 51(4) : 613 -619.
  • 4Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer, 2005; 104(9): 1794-1807.
  • 5Jackson G, Einsele H, Moreau P, et al. Bortezomib, a novel proteasomes inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev, 2005; 31(8) : 591 -602.
  • 6Saunders G. Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract, 2005 ; 11 (3) : 83 - 100.
  • 7Sinha R, Kaufman JL, Lonial S. Novel treatment approaches for patients with multiple myeloma. Clin Lymphoma Myeloma, 2006 ; 6(4) :281 -288.
  • 8Dubois D, Dhawan R, van de Velae H, et al. Descriptive and prognostic value of patients-reported outcomes. The bortezomib experience in relapsed and refractory multiple myeloma. J Clin Ocol,2006; 24(6) : 976 -982.
  • 9Andrulis M, Chatterjee M, Jain S, et al. Heat shock protein 90 alpha and beta are overexpressed in multiple myeloma cells and critically contribute to survival. Verh Dtsch Ges Pathol, 2007 ; 91 (1) :30 -337.
  • 10Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell ( DC ) -mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 2007; 109 ( 11 ) : 4839 - 4845.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部